50 mg OLE Data Expected in September 2025: The ongoing OLE study continues to enroll, and active study participants are currently receiving the 50 mg dose of nomlabofusp. Larimar plans to provide an ...

The Asia–Pacific region accounts for more than half of all global clinical trials activity and the number is expected to continue expanding, driven by the increasing incidence of cancer, a large ...